PDCD1 and neoplasm: Moon EK et al. reported that the combination of TCR-T cell therapy with PD-1 antibody reduced hypofunctionality in tumor-infiltrating lymphocytes (TILs) and augmented the efficacy of overt metastatic T cells under conditions of chronic antigenic stimulation (Moon et al., 2016).